Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, metastatic

1181 - A phase II study of the cell cycle checkpoint kinases 1 and 2 (CHK1/2) inhibitor (LY2606368; prexasertib) in sporadic triple negative breast cancer (TNBC)


09 Oct 2016


Breast cancer, metastatic


Fatima Karzai


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


F. Karzai1, A. Zimmer2, S. Lipkowitz2, C.M. Annunziata2, B. Parker2, N. Houston2, I. Ekwede2, E.C. Kohn2, J. Lee2

Author affiliations

  • 1 National Institute On Miniority Health And Health Disparities, National Institutes of Health, 20892 - Bethesda/US
  • 2 Women's Malignancies Branch, National Cancer Institute, 20892 - Rockville/US


Abstract 1181


CHK1/2 are major cell cycle regulators in tumors with p53 dysfunction, such as TNBC. Second-generation CHK1/2 inhibitor, prexasertib monomesylate monohydrate, showed preliminary single agent activity in advanced cancer pts. We hypothesize that prexasertib may yield clinical benefit in sporadic TNBC pts.


Eligible pts have recurrent TNBC with no deleterious germline BRCA mutation or no family history of hereditary breast and ovarian cancer syndrome; good end organ function and safely biopsiable disease. Prexasertib was administered at 105 mg/m2 IV once every 14 days on a 28-day cycle. Response was assessed every 2 cycles by RECISTv1.1 and safety by CTCAEv4 per cycle. Primary endpoint is overall response rate (ORR). Optimal two- stage design was used; if ≥1 response is seen in the first 9 pts, then accrual continues to 24 pts per cohort.


9 wild type BRCA TNBC pts have been treated in the first stage (median age 55.3 yrs [29-72 yrs] and median ECOG PS 1 [0-1]). The median number of prior therapies was 4 (2-10). 1 PR (3 mo) was observed (ORR 11%). 4 of 9 evaluable pts attained SD > 3 mo (median 4.5 mo [3-5]). Grade 3/4 AEs include neutropenia (89%), anemia (33%) and thrombocytopenia (22%). The median duration of grade 3/4 neutropenia was 5.5 (3-19) days. Grade 3/4 neutropenia resolved to less than grade 3/4 within 7 days in 5/9 pts. 1 pt required dose reduction to DL-1 (80 mg/m2) due to grade 4 neutropenia. 6 pts required GCSF support to avoid treatment delays. 3 pts received pRBC transfusion due to grade 2/3 anemia. 1 pt with grade 3 thrombocytopenia required platelet transfusion to avoid procedure-related bleeding.


Prexasertib monotherapy showed modest single agent activity in sporadic TNBC pts and continues to enroll in second stage. Tri-lineage marrow toxicity was observed. Prophylactic GCSF should be considered.

Clinical trial identification


Legal entity responsible for the study

National Cancer Institute, NIH Rockville, MD USA


This work was funded by the Intramural Program of the Center for Cancer Research, NCI, National Institutes of Health, USA.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings